First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)

被引：0
|
作者：
Lorenzi, M. [1 ]
Dal Maso, A. [1 ]
Ferro, A. [1 ]
Polo, V. [2 ]
Scattolin, D. [1 ]
Macerelli, M. [3 ]
Follador, A. [3 ]
Targato, G. [3 ]
Indraccolo, S. [4 ]
Frega, S. [5 ]
Menis, J. [1 ]
Bonanno, L. [5 ]
Guarneri, V. [1 ]
Conte, P. F. [1 ]
Pasello, G. [1 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[2] Ca Foncello Hosp, Oncol Unit, AULSS 2 Marca Trevigiana, Treviso, Italy
[3] Azienda Sanit Univ Integrata Udine, Santa Maria Misericordia Hosp, Dept Med Oncol, Udine, Italy
[4] Veneto Inst Oncol IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy
[5] Veneto Inst Oncol IOV IRCCS, Div Med Oncol 2, Padua, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149P
引用
收藏
页码：S779 / S779
页数：1
相关论文
共 50 条
  • [41] Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
    Shin, Ji Eun
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Shim, Byoung Yong
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [42] Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
    Sakata, Yoshihiko
    Saito, Go
    Sakata, Shinya
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shibaki, Ryota
    Okada, Asuka
    Yokoyama, Toshihide
    Matsumoto, Hirotaka
    Otsuki, Taiichiro
    Sato, Yuki
    Junji, Uchida
    Tsukita, Yoko
    Inaba, Megumi
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Morinaga, Jun
    Sakagami, Takuro
    LUNG CANCER, 2023, 186
  • [43] POST-PROGRESSION AND SAFETY OUTCOMES WITH FIRST-LINE (1L) AMIVANTAMAB PLUS LAZERTINIB VERSUS OSIMERTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH COMMON EGFR MUTATIONS: IMPLICATIONS FOR BEST MANAGEMENT PRACTICES
    Smith, Sarah
    Spira, Alexander I.
    Nguyen, Danny
    Sethi, Seema
    Gadgeel, Shirish
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [44] A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Yanxia Liu
    Yuan Gao
    Ying Wang
    Cong Zhao
    Zhiyun Zhang
    Baolan Li
    Tongmei Zhang
    BMC Cancer, 22
  • [45] A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Liu, Yanxia
    Gao, Yuan
    Wang, Ying
    Zhao, Cong
    Zhang, Zhiyun
    Li, Baolan
    Zhang, Tongmei
    BMC CANCER, 2022, 22 (01)
  • [46] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated
    Wang, Q.
    Xu, A.
    Ma, C.
    Wang, T.
    Liu, P.
    Duan, Y.
    Kong, T.
    Chen, G.
    Jia, X.
    Shang, K.
    Yang, G.
    Zhang, G.
    Yu, F.
    Wang, H.
    Chen, H.
    ANNALS OF ONCOLOGY, 2023, 34
  • [47] Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US
    Gautam, S.
    Herms, L.
    Bartolome, L.
    Pastel, M.
    Wilner, K.
    Fisher, M.
    Ivanova, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S618 - S619
  • [48] First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C.
    Ho, G.
    Chai, C.
    Alip, A. Bt
    Pang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S981 - S982
  • [49] Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
    Cardona, Andres F.
    Ruiz-Patino, Alejandro
    Recondo, Gonzalo
    Martin, Claudio
    Raez, Luis
    Samtani, Suraj
    Minata, Jose Nicolas
    Blaquier, Juan Bautista
    Enrico, Diego
    Burotto, Mauricio
    Ordonez-Reyes, Camila
    Chamorro, Diego F.
    Garcia-Robledo, Juan Esteban
    Corrales, Luis
    Zatarain-Barron, Zyanya Lucia
    Mas, Luis
    Sotelo, Carolina
    Ricaurte, Luisa
    Santoyo, Nicolas
    Cuello, Mauricio
    Mejia, Sergio
    Jaller, Elvira
    Vargas, Carlos
    Carranza, Hernan
    Otero, Jorge
    Rodriguez, July
    Archila, Pilar
    Bermudez, Maritza
    Gamez, Tatiana
    de Lima, Viadmir Cordeiro
    Freitas, Helano
    Russo, Alessandro
    Polo, Carolina
    Malapelle, Umberto
    Perez, Diego de Miguel
    Rolfo, Christian
    Viola, Lucia
    Rosell, Rafael
    Arrieta, Oscar
    CLINICAL LUNG CANCER, 2022, 23 (06) : 522 - 531
  • [50] Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)
    Chamorro, D. F.
    Ruiz-Patino, A.
    Recondo, G.
    Martin, C.
    Raez, L.
    Samtani, S.
    Minata, J. N.
    Blaquier, J. B.
    Enrico, D.
    Burotto, M.
    Ordonez-Reyes, C.
    Garcia-Robledo, J. B.
    Corrales, L.
    Zatarain-Barron, L.
    Mas, L.
    Sotelo, C.
    Ricaurte, L.
    Santoyo, N.
    Cuello, M.
    Mejia, S.
    Jaller, E.
    Vargas, C.
    Carranza, H.
    Otero, J.
    Rodriguez, J.
    Archila, P.
    Bermudez, M.
    Gamez, T.
    de Lima, V. Cordeiro
    Freitas, H.
    Russo, A.
    Polo, C.
    Malapelle, U.
    de Miguel-Perez, D.
    Rolfo, C.
    Viola, L.
    Rossell, R.
    Arrieta, O.
    Cardona, A. F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S585 - S585
12345